SG11201909718QA - Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors - Google Patents
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitorsInfo
- Publication number
- SG11201909718QA SG11201909718QA SG11201909718QA SG11201909718QA SG 11201909718Q A SG11201909718Q A SG 11201909718QA SG 11201909718Q A SG11201909718Q A SG 11201909718QA SG 11201909718Q A SG11201909718Q A SG 11201909718QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bangalore
- pct
- rule
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 title abstract 2
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003650 oxygenase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 240000000662 Anethum graveolens Species 0.000 abstract 1
- 102100034362 E3 ubiquitin-protein ligase KCMF1 Human genes 0.000 abstract 1
- 101100397797 Homo sapiens KCMF1 gene Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000004020 Oxygenases Human genes 0.000 abstract 1
- 108090000417 Oxygenases Proteins 0.000 abstract 1
- 150000001565 benzotriazoles Chemical class 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FIGC 2 0 2 0.01 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT o mons °nolo Dill mcino Imo oimIE (10) International Publication Number WO 2018/197997 Al (51) International Patent Classification: A61K 31/4192 (2006.01) A61K 31/5377 (2006.01) A61K 31/454 (2006.01) A61P 35/00 (2006.01) A61K 31/496 (2006.01) (21) International Application Number: PCT/IB2018/052710 (22) International Filing Date: 19 April 2018 (19.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/494,820 24 April 2017 (24.04.2017) US 15/899,707 20 February 2018 (20.02.2018) US (71) Applicant: AURIGENE DISCOVERY TECH- NOLOGIES LIMITED [IN/IN]; 39-40, KIADB Industri- al Area, Electronic City Phase II, Hosur Road, Karnataka, Bangalore 560100 (IN). (72) Inventors: NELLORE, Kavitha; B-502, Akme Ballet, Outer Ring Road, Doddanekundi, Karnataka, Bangalore 560037 (IN). HOSAHALLI, Subramanya; A 103, Temple Meadows, # 3, 27th Cross, Banashankari, 2nd Stage, Kar- nataka, Bangalore 560070 (IN). (74) Agent: SURAPUREDDY, Padmaja; spiProPAT Intellec- tual Property Solutions, 4th Floor, Above Apollo Clinic, Suresh Square, Plot No 1-58/91/SS, Survey No 228 & 229/1, Madinaguda, Miyapur Hyderabad 500 049 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) (54) Title: METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXY- GENATE INHIBITORS Compound 1 sensitivity across cell line panel 1-1 N 01 01 N 01 1-1 (57) : The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the 0 formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R1, R2 and R which have the meanings given in the specification, and pharmaceutically acceptable salts thereof. 3 [Continued on next page] C WO 2018/197997 Al MIDEDIMOMMIDEFIEDEMEIMOIMOHMEMOIMIE Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/494,820 US9937155B2 (en) | 2013-02-25 | 2017-04-24 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| US15/899,707 US20180369206A1 (en) | 2017-04-24 | 2018-02-20 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| PCT/IB2018/052710 WO2018197997A1 (en) | 2017-04-24 | 2018-04-19 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909718QA true SG11201909718QA (en) | 2019-11-28 |
Family
ID=65803213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909718Q SG11201909718QA (en) | 2017-04-24 | 2018-04-19 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20220241246A1 (en) |
| EP (2) | EP3915557A1 (en) |
| JP (2) | JP7225114B2 (en) |
| KR (1) | KR20190140005A (en) |
| CN (1) | CN110662539B (en) |
| AU (1) | AU2018260390B2 (en) |
| BR (1) | BR112019022331A2 (en) |
| CA (1) | CA3060390A1 (en) |
| CY (1) | CY1124702T1 (en) |
| DK (1) | DK3615027T3 (en) |
| EA (1) | EA201992528A1 (en) |
| ES (1) | ES2889100T3 (en) |
| HR (1) | HRP20211462T1 (en) |
| HU (1) | HUE056485T2 (en) |
| IL (1) | IL270066B2 (en) |
| LT (1) | LT3615027T (en) |
| MA (1) | MA48459B1 (en) |
| MD (1) | MD3615027T2 (en) |
| MX (1) | MX2019012640A (en) |
| PH (1) | PH12019502402A1 (en) |
| PL (1) | PL3615027T3 (en) |
| PT (1) | PT3615027T (en) |
| RS (1) | RS62519B1 (en) |
| SG (1) | SG11201909718QA (en) |
| SI (1) | SI3615027T1 (en) |
| TW (1) | TWI821180B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020016929A8 (en) * | 2018-02-20 | 2022-06-28 | Agios Pharmaceuticals Inc | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES |
| KR102514860B1 (en) * | 2020-12-01 | 2023-03-29 | 한국과학기술연구원 | Biphenyl pyrrolidine and biphenyl dihydroimidazole derivatives for inhibiting activity of 5-HT7 serotonin receptor and pharmaceutical composition comprising the same as an active ingredient |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| ES2882797T3 (en) | 2009-04-02 | 2021-12-02 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| PT3019482T (en) * | 2013-02-25 | 2018-11-28 | Aurigene Discovery Tech Ltd | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
-
2018
- 2018-04-19 LT LTEPPCT/IB2018/052710T patent/LT3615027T/en unknown
- 2018-04-19 RS RS20211150A patent/RS62519B1/en unknown
- 2018-04-19 EP EP21184786.8A patent/EP3915557A1/en active Pending
- 2018-04-19 CA CA3060390A patent/CA3060390A1/en active Pending
- 2018-04-19 KR KR1020197034384A patent/KR20190140005A/en active IP Right Grant
- 2018-04-19 HU HUE18723602A patent/HUE056485T2/en unknown
- 2018-04-19 EP EP18723602.1A patent/EP3615027B1/en active Active
- 2018-04-19 SI SI201830423T patent/SI3615027T1/en unknown
- 2018-04-19 HR HRP20211462TT patent/HRP20211462T1/en unknown
- 2018-04-19 ES ES18723602T patent/ES2889100T3/en active Active
- 2018-04-19 IL IL270066A patent/IL270066B2/en unknown
- 2018-04-19 PL PL18723602T patent/PL3615027T3/en unknown
- 2018-04-19 MX MX2019012640A patent/MX2019012640A/en unknown
- 2018-04-19 JP JP2019557358A patent/JP7225114B2/en active Active
- 2018-04-19 AU AU2018260390A patent/AU2018260390B2/en active Active
- 2018-04-19 PT PT187236021T patent/PT3615027T/en unknown
- 2018-04-19 CN CN201880027155.0A patent/CN110662539B/en active Active
- 2018-04-19 BR BR112019022331-2A patent/BR112019022331A2/en unknown
- 2018-04-19 DK DK18723602.1T patent/DK3615027T3/en active
- 2018-04-19 SG SG11201909718Q patent/SG11201909718QA/en unknown
- 2018-04-19 MD MDE20200226T patent/MD3615027T2/en unknown
- 2018-04-19 MA MA48459A patent/MA48459B1/en unknown
- 2018-04-19 EA EA201992528A patent/EA201992528A1/en unknown
- 2018-04-23 TW TW107113690A patent/TWI821180B/en active
-
2019
- 2019-10-23 PH PH12019502402A patent/PH12019502402A1/en unknown
-
2021
- 2021-10-04 CY CY20211100855T patent/CY1124702T1/en unknown
- 2021-10-14 US US17/501,701 patent/US20220241246A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193406A patent/JP2023022252A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201903103VA (en) | Dual inhibitors of vista and pd-1 pathways | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201809554VA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| SG11201810571RA (en) | Compositions comprising bacterial strains | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201807980QA (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
| SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201903055UA (en) | Inhibitors of glucocorticoid receptor |